MiR-16 family as potential diagnostic biomarkers for cancer: A systematic review and meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 2, 2015, Pages 1703-1714

  Cui, Jianxiong ^a  

^a Department of Oncology Sichuan Provincial Crops Hospital of Chinese People s Armed Police Forces   (China)

Author keywords

Cancer; Diagnosis; Meta analysis; MicroRNA 16 family

Indexed keywords

MICRORNA 16;

AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; DATA ANALYSIS; DATA EXTRACTION; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MAXIMUM LIKELIHOOD METHOD; META ANALYSIS; MODEL; NEOPLASM; PARAMETERS; PROBABILITY; PROGNOSIS; PROTEIN EXPRESSION; PUBLICATION; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 84926315449     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. [1] Martinez-Perez B, de la Torre-Diez I and Lopez-Coronado M. Mobile health applications for the most prevalent conditions by the World Health Organization: review and analysis. J Med Internet Res 2013; 15: e120.
2. [2] Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P and La Vecchia C. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008; 101: 949-958.
3. [3] Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58: 398-406.
4. [4] Duffy MJ. Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med 2007; 18: 175-184.
5. [5] Srigley JR and Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol 2009; 22 Suppl 2: S2-S23.
6. [6] Silva-Santos RM, Costa-Pinheiro P, Luis A, Antunes L, Lobo F, Oliveira J, Henrique R and Jeronimo C. MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer 2013; 109: 2646-2653.
7. [7] Ma L, Zhao J, Li T, He Y, Wang J, Xie L, Qin X and Li S. Association between Tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol 2014; 9: 74.
8. [8] Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, Wong YN, Chan FK, Yu J and Sung JJ. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012; 61: 739-745.
9. [9] Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA and Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-2714.
10. [10] Fakih MG and Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park) 2006; 20: 579-587; discussion 588, 594, 596 passim.
11. [11] Ferracin M, Veronese A and Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010; 10: 297-308.
12. [12] Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA and Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536.
13. [13] Zamora J, Abraira V, Muriel A, Khan K and Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
14. [14] Deeks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157-162.
15. [15] Glas AS, Lijmer JG, Prins MH, Bonsel GJ and Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-1135.
16. [16] Monzo M, Navarro A, Bandres E, Artells R, Moreno I, Gel B, Ibeas R, Moreno J, Martinez F, Diaz T, Martinez A, Balague O and Garcia-Foncillas J. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 2008; 18: 823-833.
17. [17] Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002; 21: 1237-1256.
18. [18] Jones CM and Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg 2005; 79: 16-20.
19. [19] Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
20. [20] Jackson D, White IR and Thompson SG. Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med 2010; 29: 1282-1297.
21. [21] Deeks JJ, Macaskill P and Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-893.
22. [22] Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, Dai J, Ma H, Hu Z, Shen H, Xu Y and Jin G. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer 2014; 110: 2291-2299.
23. [23] Tsukamoto O, Miura K, Mishima H, Abe S, Kaneuchi M, Higashijima A, Miura S, Kinoshita A, Yoshiura Ki and Masuzaki H. Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecol Oncol 2014; 132: 715-21.
24. [24] Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, Wang J, Li L, Zhou X, Li N, Pan H, Zhang J, Zen K, Zhang CY and Zhang C. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 2013; 132: 116-127.
25. [25] Zeng Z, Wang J, Zhao L, Hu P, Zhang H, Tang X, He D and Tang S. Potential role of microRNA-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS One 2011; 8: e73278.
26. [26] Liu X, Luo HN, Tian WD, Lu J, Li G, Wang L, Zhang B, Liang BJ, Peng XH, Lin SX, Peng Y and Li XP. Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma. Cancer Biol Ther 2013; 14.
27. [27] Wang X, Wu X, Yan L and Shao J. [Serum miR-103 as a potential diagnostic biomarker for breast cancer]. Nan Fang Yi Ke Da Xue Xue Bao 2012; 32: 631-634.
28. [28] Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, Hamdy FC, Catto JW. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 2012; 107: 123-128.
29. [29] Maclellan SA, Lawson J, Baik J, Guillaud M, Poh CF and Garnis C. Differential expression of miRNAs in the serum of patients with high-risk oral lesions. Cancer Med 2012; 1: 268-274.
30. [30] Fang C, Zhu DX, Dong HJ, Zhou ZJ, Wang YH, Liu L, Fan L, Miao KR, Liu P, Xu W and Li JY. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol 2012; 91: 553-559.
31. [31] Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T and Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2011; 106: 768-774.
32. [32] Qu KZ, Zhang K, Li H, Afdhal NH and Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-360.
33. [33] Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC and Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011; 77: 1265 e1269-1216.
34. [34] Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zollner H, Reinacher-Schick A, Schmiegel W, Hahn SA and Schroers R. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011; 117: 3140-3146.
35. [35] Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251: 499-505.
36. [36] Heneghan HM, Miller N, Kelly R, Newell J and Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010; 15: 673-682.
37. [37] Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M and Seki N. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009; 125: 345-352.
38. [38] Sanfiorenzo C, Ilie MI, Belaid A, Barlesi F, Mouroux J, Marquette CH, Brest P and Hofman P. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One 2013; 8: e54596.
39. [39] Deeks JJ and Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2013; 329: 168-169.
40. [40] Abd-El-Fattah AA, Sadik NA, Shaker OG and Aboulftouh ML. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys 2013; 67: 875-884.
41. [41] Wang D, Mou ZY, Zhai JX, Zong HX and Zhao XD. [Application of Stata software to test heterogeneity in meta-analysis method]. Zhong-hua Liu Xing Bing Xue Za Zhi 2008; 29: 726-729.